Drug-Target Information | ||||||||
---|---|---|---|---|---|---|---|---|
Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
salmeterol | beta-1 adrenergic receptor | small molecule | NA | drugbank , DGIDB | Maintenance[MeSHID:D008283] Bronchospasm Exercise-Induced[MeSHID:D001250] Asthma[MeSHID:D001249] Chronic Obstructive Airway Disease[MeSHID:D029424] Inspiration function[MeSHID:D001239] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.35 | approved | inverse agonist |
salmeterol | adrenergic receptor beta-2 | NA | Successful target | TTD , DGIDB | Maintenance[MeSHID:D008283] Bronchospasm Exercise-Induced[MeSHID:D001250] Asthma[MeSHID:D001249] Chronic Obstructive Airway Disease[MeSHID:D029424] Inspiration function[MeSHID:D001239] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
2.08 | approved | unknown |
salmeterol | beta-2 adrenergic receptor | small molecule | NA | drugbank , DGIDB | Maintenance[MeSHID:D008283] Bronchospasm Exercise-Induced[MeSHID:D001250] Asthma[MeSHID:D001249] Chronic Obstructive Airway Disease[MeSHID:D029424] Inspiration function[MeSHID:D001239] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
2.08 | approved | agonist |
salmeterol | adrenergic receptor beta-2 | NA | Successful target | TTD , DGIDB | Maintenance[MeSHID:D008283] Bronchospasm Exercise-Induced[MeSHID:D001250] Asthma[MeSHID:D001249] Chronic Obstructive Airway Disease[MeSHID:D029424] Inspiration function[MeSHID:D001239] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
2.08 | approved | agonist |
salmeterol | beta-3 adrenergic receptor | small molecule | NA | drugbank | Maintenance[MeSHID:D008283] Bronchospasm Exercise-Induced[MeSHID:D001250] Asthma[MeSHID:D001249] Chronic Obstructive Airway Disease[MeSHID:D029424] Inspiration function[MeSHID:D001239] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | inverse agonist |
click here to return to the previous page |